CCT196969
Cat. No.：YN350126
CAS No. ：1163719-56-9
| 产品名称: | CCT196969 |
| CAS No.: | 1163719-56-9 |
| Chemical Name: | N-[4-[(3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-8-yl)oxy]-2-fluorophenyl]-N'-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]-urea |
| Synonyms: | CCT196969;1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea;1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea;GTPL9815;BCP19551;BDB |
| 分子量: | 513.52 |
| 分子式: | C₂₇H₂₄FN₇O₃ |
| SMILES: | O=C1NC2=NC=CC(OC3=CC=C(NC(NC4=CC(C(C)(C)C)=NN4C5=CC=CC=C5)=O)C(F)=C3)=C2N=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | CCT196969 是一种泛-Raf 抑制剂，抑制B-Raf，BRafV600E和CRAF，IC50分别为 0.1, 0.04, 和 0.01 μM。 |
| IC50和靶点: | [{name:"BRafV600E:0.04 μM (IC50)"},{name: "Braf:0.1 μM (IC50)"},{name: "CRAF:0.01 μM (IC50)"},{name: "LCK:0.02 μM (IC50)"},{name: "SRC:0.03 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Girotti, M.R., Lopes, F.J.P., Preece, N., et al.Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaCancer Cell31(3),85-96(2017)
